Related Experiment Video
Updated: May 31, 2025
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Targeting SLC4A4: A Novel Approach in Colorectal Cancer Drug Repurposing
Krunal Pawar1, Pramodkumar P Gupta2, Pooran Singh Solanki3,4
1Amity Institute of Biotechnology, Amity University Rajasthan, SP-1, Kant Kalwar, RIICO Industrial Area, NH-11C, Jaipur 303002, Rajasthan, India.
Background:
Colorectal cancer (CRC) is a complex and increasingly prevalent malignancy with significant challenges in its treatment and prognosis. This study aims to explore the role of the SLC4A4 transporter as a biomarker in CRC progression and its potential as a therapeutic target, particularly in relation to tumor acidity and immune response.
Methods:
The study utilized computational approaches, including receptor-based virtual screening and high-throughput docking, to identify potential SLC4A4 inhibitors. A model of the human SLC4A4 structure was generated based on CryoEM data (PDB ID 6CAA), and drug candidates from the DrugBank database were evaluated using two computational tools (DrugRep and CB-DOCK2).
Results:
The study identified the compound (5R)-N-[(1r)-3-(4-hydroxyphenyl)butanoyl]-2-decanamide (DB07991) as the best ligand, demonstrating favorable binding affinity and stability. Molecular dynamics simulations revealed strong protein-ligand interactions with consistent RMSD (~0.25 nm), RMSF (~0.5 nm), compact Rg (4.0-3.9 nm), and stable SASA profiles, indicating that the SLC4A4 structure remains stable upon ligand binding.
Conclusions:
The findings suggest that DB07991 is a promising drug candidate for further investigation as a therapeutic agent against CRC, particularly for targeting SLC4A4. This study highlights the potential of computational drug repositioning in identifying effective treatments for colorectal cancer.
Insights
Researchers identified a promising compound, DB07991, targeting the SLC4A4 transporter to treat colorectal cancer (CRC). This computational approach offers new therapeutic strategies for CRC by modulating tumor acidity and immune response.
Area of Science:
- Oncology
- Computational Biology
- Pharmacology
Background:
- Colorectal cancer (CRC) presents significant treatment and prognosis challenges.
- The SLC4A4 transporter's role in CRC progression, tumor acidity, and immune response requires further investigation.
Purpose of the Study:
- To explore SLC4A4 as a potential biomarker and therapeutic target in colorectal cancer.
- To identify potential SLC4A4 inhibitors using computational methods.
Main Methods:
- Receptor-based virtual screening and high-throughput docking were employed.
- A human SLC4A4 model (PDB ID 6CAA) was generated.
- Drug candidates from DrugBank were evaluated using DrugRep and CB-DOCK2.
Main Results:
- The compound (5R)-N-[(1r)-3-(4-hydroxyphenyl)butanoyl]-2-decanamide (DB07991) emerged as the top ligand with favorable binding affinity and stability.
- Molecular dynamics simulations confirmed stable protein-ligand interactions and SLC4A4 structure integrity.
Conclusions:
- DB07991 shows promise as a therapeutic agent for colorectal cancer by targeting SLC4A4.
- Computational drug repositioning is a viable strategy for discovering novel CRC treatments.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
02:56Treatment Resistant Cancers